|Bid||45.48 x 3200|
|Ask||45.60 x 4000|
|Day's range||45.03 - 46.13|
|52-week range||44.30 - 63.69|
|Beta (3Y monthly)||0.87|
|PE ratio (TTM)||15.12|
|Earnings date||25 Apr 2019|
|Forward dividend & yield||1.64 (3.44%)|
|1y target est||57.80|
These two marijuana stocks reported very different results last quarter. Plus, how Abbott's challenging Dexcom in diabetes, and what's next for Bristol-Myers following its Celgene acquisition.
Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol-Myers Squibb Company announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation , of an exchange offer for any and all outstanding notes issued by Celgene for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb and cash.
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $46.02, marking a -1.03% move from the previous day.
The fat lady is getting ready to sing with this big pharma deal. Celgene shareholders will soon have a decision to make.
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
The deal, announced in January, was a hard sell to Bristol shareholders from the start. The approval concludes a tumultuous period for Bristol, which saw pushback from institutional investors.
Bristol-Myers Squibb Company (BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company’s pending merger with Celgene Corporation (CELG) at the Special Meeting of Stockholders. “We are pleased with the outcome of today’s Special Meeting and thank our shareholders for their support for this combination,” said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. “Together with Celgene, we will create a premier innovative biopharma company with leading scientific capabilities that is well positioned to address the needs of patients through high-value innovative medicines.
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Celgene shareholders also gave their support for the deal, which is expected to close in the third quarter but awaits US regulatory approval. “Together with Celgene, we will create a premier innovative biopharma company with leading scientific capabilities that is well positioned to address the needs of patients through high-value innovative medicines,” Bristol-Myers chairman and chief executive Giovanni Caforio said in a statement.
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
The U.S. Environmental Protection Agency (EPA) has recognized Bristol-Myers Squibb Company (BMY) with an ENERGY STAR® Partner of the Year Sustained Excellence Award for its outstanding contributions and leadership to improve the energy efficiency of facilities worldwide. Bristol-Myers Squibb has earned the ENERGY STAR® Partner of the Year award for the past five consecutive years. “We are proud to have our commitment to environmental responsibility recognized with the ENERGY STAR Partner of the Year Sustained Excellence Award,” said Carol Ryerkerk Powell, vice president of Environment, Health, Safety and Sustainability, Bristol-Myers Squibb.
Columbia fund manager David King also likes a group of convertible preferred-stock issues, which offer higher yields than common shares.
Jeff Smith’s Starboard Value wrestled the crown from Elliott to become the most prolific activist investor in the first quarter of 2019, with new campaigns for a strategic rethink at companies as diverse as drugmaker Bristol-Myers Squibb, ecommerce business eBay and pizza chain Papa John’s. Starboard’s seven new campaigns eclipsed the four launched by Paul Singer’s Elliott Management, which was the most prolific for the previous seven consecutive quarters, and for 10 of the 11 previous quarters, according to data compiled by the boutique investment bank Lazard. Elliott still manages significantly more money — it has assets under management of more than $35bn, compared to Starboard’s $5.5bn, according to regulatory filings — but Starboard has been bolstering its reputation as a formidable opponent for companies it says are not being run to the maximum value for shareholders.
Bristol-Myers Squibb (BMY) closed the most recent trading day at $45.98, moving -1.73% from the previous trading session.
Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.